Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.

Nguyen MC, Tu GH, Koprivnikar KE, Gonzalez-Edick M, Jooss KU, Harding TC.

Cancer Immunol Immunother. 2010 Sep;59(9):1313-23. doi: 10.1007/s00262-010-0858-5. Epub 2010 May 25.

PMID:
20499060
2.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
4.

Immunotherapeutics in development for prostate cancer.

Harzstark AL, Small EJ.

Oncologist. 2009 Apr;14(4):391-8. doi: 10.1634/theoncologist.2008-0240. Epub 2009 Apr 2. Review.

5.

Clinical experience with CD64-directed immunotherapy. An overview.

Curnow RT.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5. Review.

PMID:
9435876
6.

GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.

Ward JE, McNeel DG.

Expert Opin Biol Ther. 2007 Dec;7(12):1893-902. Review.

PMID:
18034654
7.

Prostate cancer immunotherapy.

McNeel DG.

Curr Opin Urol. 2007 May;17(3):175-81. Review.

PMID:
17414515
8.

Advances in specific immunotherapy for prostate cancer.

Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.

Eur Urol. 2008 Apr;53(4):694-708. Epub 2007 Nov 26. Review.

PMID:
18061335
9.

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.

Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ.

Urology. 2003 Dec 29;62 Suppl 1:128-33. Review.

PMID:
14747050
10.

Recent clinical development of dendritic cell-based immunotherapy for prostate cancer.

Rini B.

Expert Opin Biol Ther. 2004 Nov;4(11):1729-34. Review.

PMID:
15500401
11.

Markers and meaning of primary treatment failure.

Swindle PW, Kattan MW, Scardino PT.

Urol Clin North Am. 2003 May;30(2):377-401. Review.

PMID:
12735513
12.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

13.

The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Ferrari AC, Quinn DI.

Clin Adv Hematol Oncol. 2011 Dec;9(12 Suppl 28):1-14; quiz 15-6. Review.

PMID:
22407145
14.

The potential for prostate cancer immunotherapy.

Rini BI, Small EJ.

Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S117-25. Review. Erratum in: Crit Rev Oncol Hematol. 2012 Sep;83(3):452.

PMID:
12850532
15.

Target molecules in specific immunotherapy against prostate cancer.

Harada M, Noguchi M, Itoh K.

Int J Clin Oncol. 2003 Aug;8(4):193-9. Review.

PMID:
12955573
16.

Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins.

Galustian C, Vyakarnam A, Elhage O, Hickman O, Dasgupta P, Smith RA.

Biochem Soc Trans. 2011 Oct;39(5):1433-6. doi: 10.1042/BST0391433. Review.

PMID:
21936828
17.

Dendritic cell-based immunotherapy for prostate cancer.

Jähnisch H, Füssel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, Rieber EP, Wirth MP, Schmitz M.

Clin Dev Immunol. 2010;2010:517493. doi: 10.1155/2010/517493. Epub 2010 Nov 4. Review.

18.

[Active specific immune therapy of prostate gland cancer].

Chakŭrov S, Minchev M.

Khirurgiia (Sofiia). 2002;58(1):32-8. Review. Bulgarian. No abstract available.

PMID:
12515033
19.

Immunotherapy for metastatic prostate cancer.

Drake CG.

Urol Oncol. 2008 Jul-Aug;26(4):438-44. doi: 10.1016/j.urolonc.2007.03.029. Epub 2007 Dec 21. Review.

20.

The current role and limitations of surrogate endpoints in advanced prostate cancer.

Gomella LG, Oliver Sartor A.

Urol Oncol. 2014 Jan;32(1):28.e1-9. doi: 10.1016/j.urolonc.2012.10.001. Epub 2013 Feb 20. Review.

PMID:
23433893

Supplemental Content

Support Center